Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-12-27 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2022 first extraordinary general meeting of shareholders for 科美诊断技术股份有限公司. It includes information about the meeting date, voting methods, agenda items, shareholder eligibility, registration procedures, and proxy authorization forms. There is no financial data, earnings, or management discussion. The document is not a report itself but a formal announcement and invitation to a shareholder meeting, including proxy voting instructions. This fits the definition of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2021-12-27 Chinese
科美诊断技术股份有限公司2021年限制性股票激励计划（草案）
Share Issue/Capital Change Classification · 95% confidence The document is a detailed draft of a 2021 restricted stock incentive plan by 科美诊断技术股份有限公司. It includes extensive information about the stock incentive plan, such as legal basis, purpose, management, scope, stock quantity, pricing, vesting conditions, performance targets, and implementation procedures. It references relevant laws and regulations, the company's articles of association, and supervisory opinions. The document is lengthy (15,000 characters) and contains substantive content about the stock incentive plan itself, not merely an announcement or summary. This type of document is a detailed disclosure related to capital changes and share issuance, specifically about a restricted stock incentive plan involving issuance of new shares to employees and management. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2021-12-27 Chinese
上海荣正投资咨询股份有限公司关于科美诊断技术股份有限公司2021年限制性股票激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report regarding a 2021 Restricted Stock Incentive Plan for the company 科美诊断技术股份有限公司. It includes detailed descriptions of the stock incentive plan, its terms, conditions, pricing, allocation, and compliance with relevant laws and regulations. The report is prepared by an independent financial advisor and provides professional opinions on the plan's legality, feasibility, and fairness to shareholders. It is not a general annual report, earnings release, or a simple announcement but a specialized advisory report focused on a stock incentive plan. This type of document fits the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives. The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-12-27 Chinese
科美诊断技术股份有限公司独立董事关于第一届董事会第十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 16th meeting of the first board of directors of a company. It focuses on the review and approval of a 2021 restricted stock incentive plan and its assessment management measures. The document references compliance with company law, securities law, stock exchange listing rules, and other regulatory frameworks. It is a formal opinion letter rather than a financial report, earnings release, or regulatory filing. The content is about governance and approval of stock incentive plans, which is typically part of board or management information disclosures. The document length is 2374 characters, which is relatively short and does not contain financial statements or detailed financial data. It is not an announcement of a report but an opinion on board matters. Therefore, the best classification is Board/Management Information (MANG).
2021-12-27 Chinese
科美诊断技术股份有限公司2021年限制性股票激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is a list of recipients for a 2021 restricted stock incentive plan, detailing allocation of restricted shares to directors, senior management, and other employees. It includes specific share quantities and percentages related to the incentive plan. This is a disclosure related to share-based compensation and equity incentives, which typically falls under Remuneration Information filings. The document is not a full annual report, audit report, or earnings release, nor is it a voting result or capital change announcement. It specifically details compensation-related stock incentives, matching the Remuneration Information category.
2021-12-27 Chinese
科美诊断技术股份有限公司监事会关于公司2021年限制性股票激励计划（草案）的核查意见
Board/Management Information Classification · 90% confidence The document is a supervisory board's verification opinion on the company's 2021 restricted stock incentive plan draft. It discusses compliance with laws and regulations related to stock incentive plans, eligibility of incentive recipients, and the plan's alignment with legal requirements. It does not contain financial statements or earnings data, nor is it an announcement of a meeting or voting results. It is a formal opinion related to management and governance matters concerning stock incentives. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to management decisions and governance matters such as stock incentive plans.
2021-12-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.